Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in... Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. Mostrar más
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in...
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation...
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.31 | -8.95953757225 | 3.46 | 3.6 | 3.11 | 858106 | 3.31388641 | CS |
| 4 | -1.25 | -28.4090909091 | 4.4 | 5.025 | 3.11 | 797567 | 3.79451573 | CS |
| 12 | -1.82 | -36.6197183099 | 4.97 | 6.52 | 3.11 | 611859 | 4.85022653 | CS |
| 26 | -1.08 | -25.5319148936 | 4.23 | 7.25 | 3.11 | 894588 | 5.00973624 | CS |
| 52 | -4.41 | -58.3333333333 | 7.56 | 8.885 | 3.11 | 982435 | 5.82591052 | CS |
| 156 | -19.85 | -86.3043478261 | 23 | 29.88 | 3.11 | 1033996 | 9.71227094 | CS |
| 260 | -19.85 | -86.3043478261 | 23 | 29.88 | 3.11 | 1033996 | 9.71227094 | CS |
Monksdream
4 meses hace
Monksdream
4 meses hace
Monksdream
8 meses hace
retireat40
1 año hace
makinezmoney
1 año hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
